Beam hits hemoglobin goal in first base editing clinical data, reports death tied to conditioning drug

Beam Therapeutics has presented the first clinical data on its base editing technology. All four sickle cell disease patients in the efficacy cohort had fetal hemoglobin levels above Beam’s target—and the result achieved by Vertex’s rival therapy—but one patient died, likely as a result of the conditioning regimen.